Furazolidone and Serotonin Syndrome: Is there any Association?

Karamanakos, Petros N

doi:10.1590/s1807-59322008000400024

Cited by 5 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 One of its major metabolite, amino-2-oxazolidone, can non-selectively inhibit the monoamine oxidase activity, interact with metabolism of tyramine and cause dose-dependent gastrointestinal and nervous system disorders. 38 Notably, two specific AEs were reported in previous studies. One was disulfiram-like reaction to alcohol and the other was haemolytic anaemia in glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients.…”

Section: Discussionmentioning

confidence: 92%

Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis

Liu

et al. 2020

BMJ Open

View full text Add to dashboard Cite

ObjectivesFurazolidone containing regimen is effectivefor Helicobacter pylori (H. pylori) infection, but its safetyremains controversial. To assess the safety of furazolidone containing regimenin H. pylori infection.DesignA systematic review and meta-analysis.Data sourcesPubMed, Embase, Cochrane Library, Web of Science and Scopus databases were systematically searched for eligible randomised controlled trials.Eligibility criteriaStudies comparing furazolidone with non-furazolidone-containing regimen, variable durations or doses of furazolidone were included.Data extraction and synthesisTwo reviewers independently selected studies and extracted data. Primary outcomes were the risk of total adverse events (AEs), serious AEs and severe AEs, expressed as relative risk (RR) with 95% CI. Secondary outcomes contained the incidence of individual adverse symptoms, AE-related treatment discontinuation and compliance.ResultsTwenty-six articles were identified from 2039 searched records, of which 14 studies (n=2540) compared furazolidone with other antibiotics. The eradication rates of furazolidone-containing regimen were higher than those of other antibiotics in both intention-to-treat (RR 1.06, 95% CI 1.01 to 1.12) and per-protocol analysis (RR 1.05, 95% CI 1.00 to 1.10). Only two serious AEs were reported in furazolidone group (2/1221, 0.16%). No significant increased risk was observed for the incidence of total AEs (RR 1.04, 95% CI 0.89 to 1.21) and severe AEs (RR 1.81, 95% CI 0.91 to 3.60). Twelve studies (n=3139) compared different durations of furazolidone, and four studies (n=343) assessed variable doses. Elevated risk of total AEs and severe AEs were only found in a high daily dose of furazolidone rather than prolonged duration. The incidence of AE-related treatment discontinuation and compliance of patients were all similar, irrespective of dose and duration adjustments.ConclusionFurazolidone-containing regimen has a similar risk of AEs and compliance as non-furazolidone-containing regimen. A low daily dose of 200 mg is well-tolerated for 14 day regimen and should be first considered.PROSPERO registration numberCRD42019137247

show abstract

Section: Discussionmentioning

confidence: 92%

Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis

Liu

et al. 2020

BMJ Open

View full text Add to dashboard Cite

show abstract

“…It is well known that the use of antibiotics is often accompanied by some undesired effects. In particular, some antibiotics, such as linezolid [23] and furazolidone [24], are able to block the function of, monoamine oxidase (MAO) enzyme, increasing the risk of certain adverse effects, such as the “cheese reaction”, serotonin syndrome [25], etc. Among others, some 2-imidazolines are also known to inhibit MAOs [26].…”

Section: Resultsmentioning

confidence: 99%

1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer

Shetnev

Baykov

Kalinin

et al. 2019

IJMS

View full text Add to dashboard Cite

Replacement of amide moiety with the 1,2,4-oxadiazole core in the scaffold of recently reported efflux pump inhibitors afforded a novel series of oxadiazole/2-imidazoline hybrids. The latter compounds exhibited promising antibacterial activity on both Gram-positive (Staphylococcus aureus, Bacillus subtilis) and Gram-negative (Escherichia coli, Pseudomonas fluorescens) strains. Furthermore, selected compounds markedly inhibited the growth of certain drug-resistant bacteria. Additionally, the study revealed the antiproliferative activity of several antibacterial frontrunners against pancreas ductal adenocarcinoma (PANC-1) cell line, as well as their type-selective monoamine oxidase (MAO) inhibitory profile.

show abstract

“…FZD works depending on its ability to crosslink DNA, especially bacterial DNA which is particularly susceptible to this drug, and leads to high levels of mutations (DrugBank, 2008). However, FZD and its metabolites 3-Amino-2-oxazolidinone (AOZ) have shown some toxic effects on the animals and induced oxidative DNA damage (Ali, 1999;Karamanakos, 2008;Jin et al, 2011). Due to the carcinogenic and mutagenic properties and its retention in the animal tissue, FDA had withdrew the approval of FZD in 1991 and later in 2002 FZD was prohibited in the field of food-producing animals (Andrew and von Eschenbach, 2008).…”

Section: Introductionmentioning

confidence: 99%

Degradation of furazolidone by bacteria Acinetobacter calcoaceticus T32, Pseudomonas putida SP1 and Proteus mirabilis V7

Zhang¹,

Niu²,

Yin³

et al. 2013

International Biodeterioration & Biodegradation

View full text Add to dashboard Cite

Furazolidone and Serotonin Syndrome: Is there any Association?

Cited by 5 publications

References 4 publications

Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis

Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis

1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer

Degradation of furazolidone by bacteria Acinetobacter calcoaceticus T32, Pseudomonas putida SP1 and Proteus mirabilis V7

Contact Info

Product

Resources

About